Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$1.25
$0.01(0.80%)
At close: 4:00 PM EDT
$1.25
$0.01(0.80%)
Day’s Range― - ―
52-Week Range$0.87 - $2.99
Previous Close$1.26
Volume536.26K
Average Volume (3M)2.40M
Market Cap
$99.30M
Enterprise Value$72.05
Total Cash (Recent Filing)$34.82M
Total Debt (Recent Filing)$877.00K
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Nov 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding72,483,850
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.80Price Target Upside444.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Covalent Drug Discovery PlatformBiomea’s proprietary covalent chemistry approach is a durable scientific differentiator. It enables selective, potentially longer‑lasting inhibition of disease drivers, supporting a defensible R&D engine that can produce multiple distinct small‑molecule candidates in oncology and metabolic disease over time.
Advancing Multiple Clinical ProgramsConcurrent progress across Phase I and II programs and near completion of enrollment represent durable pipeline de‑risking. Multiple active trials spread development risk, increase the chance of program success, and create several upcoming data inflection points that can materially validate the platform over months.
Improving Loss Trajectory And Low LeverageReported narrowing of losses (from larger prior years) alongside low debt (debt-to-equity ~0.07) strengthens financial flexibility. Improved burn reduces near-term financing pressure and low leverage preserves optionality to raise capital without heavy interest burdens while advancing clinical programs.
Bears Say
No Revenue; Persistent Negative Free Cash FlowAs a clinical‑stage biotech with no product sales, ongoing negative FCF requires external financing to sustain operations. A persistent ~-$47M TTM burn rate means runway and dilution risk are structural until partnerships, milestones, or approvals produce recurring cash inflows.
Sharply Shrinking Equity BaseCumulative losses have eroded shareholders’ equity significantly, leaving a thin capital cushion. This structural shrinkage heightens vulnerability to adverse trial outcomes, increases likelihood of dilutive financings, and reduces the firm’s ability to absorb shocks without material ownership dilution.
Shareholder Dissent On Board CompositionSignificant investor rejection of director nominees signals governance tension that can impede strategic continuity. Persistent dissent may invite activism, management distraction, or changes in oversight, introducing execution risk during a critical clinical development phase.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $2.99 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $99.30M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Nov 03, 2026 which is in 70 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Aug 05, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.103.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.23.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,483,850 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.80 (444.00% Upside)
$6.80 (444.00% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 53.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.60%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$6.80
▲(444.00% Upside)
Technical Analysis
Ownership Overview
3.71% Insiders
11.19% Mutual Funds
4.75% Other Institutional Investors
76.11% Public Companies and
Individual Investors